** Shares of drug developer Tectonic Therapeutic TECX.O rise ~104% to $52.50, set for record single-day pct gain
** TECX says its experimental drug, TX45, showed improved blood flow and reduced pressure in lungs and heart in an early-stage trial
** TECX is testing TX45 to treat patients with group 2 pulmonary hypertension, a condition where high lung blood pressure is caused by left-sided heart disease, leading to symptoms such as shortness of breath, fatigue, and swelling in the legs and feet
** TX45 was well-tolerated and had no serious side effects in patients - TECX
** The condition currently has no approved treatments
** TECX more than doubled in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。